Test brain injections plus IV antibody for HER2-positive glioblastoma
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests a combination of cells injected directly into the brain and an IV antibody to treat recurrent HER2-positive glioblastoma (or a related tumor, gliosarcoma). It may help by attacking the tumor locally in the brain while the antibody boosts the immune system’s response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and have recurrent (come-back) or hard-to-treat HER2-positive glioblastoma (or gliosarcoma).
- Your care team is planning relapse surgery (or a biopsy first for a special subgroup) and can delay surgery about 4 weeks if needed.
- You’ve had the usual glioblastoma treatments (radiation plus chemotherapy) or stopped early because of problems or intolerance; some patients may not need one chemo type if MGMT is not methylated.
- You must be well enough to tolerate treatment: life expectancy at least 3 months and good strength/ability (Karnofsky score 70 or higher).
- Your recent treatments fit the timing rules: you must not be on other cancer treatments for 2 weeks before starting; temozolomide may be allowed up to 48 hours before, and a small steroid dose (up to 4 mg/day) is allowed if medically needed.
- You must be able to have brain MRI scans and be free of major restrictions like pregnancy, certain infections, and certain immune or clotting problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This Phase 2 trial tests an individualized treatment approach for glioblastoma or gliosarcoma based on your tumor’s lab tests. It may help by matching therapy to tumor features and by checking how well this strategy works after surgery and planned radiation.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This trial tests combining an immunotherapy drug (adebrelimab) with the standard chemotherapy temozolomide, with or without hyperbaric oxygen treatment, for patients with newly diagnosed glioblastoma who have already completed standard radiation and chemotherapy. The goal is to see if this combination can improve outcomes.
This trial tests an experimental 'vaccine' made from your own immune cells (dendritic cells). The vaccine is designed to train your immune system to attack the brain tumor. It is for people whose glioblastoma has returned or progressed after standard treatment.
This trial tests a combination of two drugs—sintilimab (an immunotherapy that helps your immune system fight cancer) and low-dose bevacizumab (which blocks blood vessel growth to tumors)—for people whose glioblastoma has returned after standard treatment. The goal is to see if this combo can slow or stop the cancer with fewer side effects.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.